Evotec SE (NASDAQ:EVO - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $4.44, but opened at $4.58. Evotec shares last traded at $4.45, with a volume of 39,766 shares trading hands.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Evotec in a report on Thursday, November 7th.
Check Out Our Latest Stock Analysis on Evotec
Evotec Trading Up 2.1 %
The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The stock's fifty day simple moving average is $4.40 and its 200-day simple moving average is $4.06.
Hedge Funds Weigh In On Evotec
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new position in shares of Evotec in the 4th quarter worth about $27,000. CSS LLC IL purchased a new position in shares of Evotec in the 4th quarter worth about $50,000. Bank of America Corp DE boosted its holdings in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in shares of Evotec in the 4th quarter worth about $166,000. Finally, DCF Advisers LLC boosted its holdings in shares of Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after buying an additional 12,816 shares during the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
